Latest News

Stay up to date with the latest stock market news from around the world. From breaking news written by our finance analysts to event-driven market news on a global scale.

NYSE:CMRE
NYSE:CMREShipping

Assessing Costamare (CMRE) Valuation After Dividend Reaffirmation And Balance Sheet Progress

What Costamare’s Latest Dividend Move Signals for Investors Costamare (CMRE) recently reaffirmed its income profile by declaring a quarterly dividend of $0.115 per common share, along with scheduled payments on its Series B, C, and D preferred shares. For common shareholders, the $0.115 dividend relates to the quarter ended December 31, 2025 and is payable on February 5, 2026 to investors on record as of January 20, 2026. Preferred investors are set to receive $0.476563 per Series B share,...
NYSE:DDD
NYSE:DDDMachinery

A Look At 3D Systems (DDD) Valuation After Defense Tailwinds And MedTech Milestones

Why 3D Systems Is Back on Investor Radar 3D Systems (DDD) is drawing fresh attention after expanding its U.S. facilities, securing 510(k) clearance for its VSP Orthopedics platform, and advancing defense work supported by the National Defense Authorization Act. See our latest analysis for 3D Systems. These updates have arrived during a volatile stretch, with a 7 day share price return of 25.95% and a 30 day gain of 22.63% following a 90 day decline of 25.08%. At the same time, the 1 year...
NasdaqCM:VFF
NasdaqCM:VFFFood

Is Pomerantz’s Probe Reshaping How Investors View Village Farms’ (VFF) Governance And Growth Ambitions?

Pomerantz LLP recently announced it is investigating potential claims on behalf of investors of Village Farms International, Inc., inviting affected shareholders to contact the firm for more information. This type of investor-focused legal review can intensify scrutiny of Village Farms’ governance and disclosures, adding a new layer of risk perception around the company. We’ll now examine how this investor legal investigation could influence Village Farms International’s cannabis-focused...
NasdaqCM:CLDX
NasdaqCM:CLDXBiotechs

How Advancing Antibody Pipeline And 2027 Cash Runway At Celldex Therapeutics (CLDX) Has Changed Its Investment Story

In recent updates, Celldex Therapeutics reported progression of its antibody pipeline, including global Phase 3 trials for barzolvolimab in chronic urticarias and early-stage data for bispecific antibody CDX-622. A key insight for investors is Celldex’s cash runway reportedly extending through 2027, supporting continued development of these late- and mid-stage programs. Next, we’ll explore how this pipeline momentum, particularly the Phase 3 barzolvolimab program, shapes Celldex...
SGX:558
SGX:558Semiconductor

The Bull Case For UMS Integration (SGX:558) Could Change Following Debt-Free Penang Expansion And Richer Product Mix

UMS Integration recently reported a softer revenue patch but a slightly higher net profit, maintained its interim dividend, and continued investing heavily in capacity expansion at its Penang plant, which has temporarily pushed free cash flow into decline. An interesting angle is that the company is funding this expansion while keeping a strong cash balance, carrying no debt, and beginning shipments to a major new Malaysian customer, underscoring how a richer product mix can support...